Meeting
2022 ASCO Annual Meeting
Phase 2 pilot trial of RRx-001 as an anti-mucositis agent in patients with head and neck cancer treated with chemoradiation (PREVLAR).
Authors
Marcelo Raul Bonomi
James Cancer Hospital Solove Research Institute, The Ohio State University, Columbus, OH
Marcelo Raul Bonomi , Dukagjin Blakaj , David Sher , Rafi Kabarriti , Kyle Colvett , Seth Reiner , Vinita Takiar , Matthew Biagioli , Voichita C. Bar-Ad , Sharad Goyal , Brian C. Muzyka , Kenneth J. Niermann , Tony R. Reid , Bryan Oronsky , Nacer Abrouk , Scott Caroen , Pedro Cabrales , Stephen T. Sonis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT03515538
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6078)
DOI
10.1200/JCO.2022.40.16_suppl.6078
Abstract #
6078
Poster Bd #
70
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 2, randomized, double-blind trial of EC-18 versus placebo to mitigate the development and time course of oral mucositis from concomitant chemoradiation for head and neck cancer.
First Author: Christina Henson
Poster
2021 ASCO Annual Meeting
Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head and neck (H&N) cancer.
First Author: Daniel Osei-Fofie
Poster
2020 ASCO Virtual Scientific Program
Results of a randomized, open-label, multicenter trial to assess the safety, dose, and schedule ofRRx-001(001) in reducing incidence, severity and duration of severe oral mucositis (SOM) inpatients receiving concomitant chemoradiation (CRT) for advanced head and neck cancer (HNC).
First Author: Marcelo Raul Bonomi
Poster
2020 ASCO Virtual Scientific Program
ROMAN: Reduction in oral mucositis with avasopasem manganese (GC4419)–phase III trial in patients receiving chemoradiotherapy for locally advanced, nonmetastatic head and neck cancer.
First Author: Jon Holmlund